Phenibut: The Legal Supplement Causing Hospitalizations

← Back to articles

Phenibut (β-phenyl-γ-aminobutyric acid) is not really a dietary supplement at all. It is a centrally active drug developed and prescribed in parts of Eastern Europe that has been sold online to consumers elsewhere as a "calming nootropic" or "natural anxiety aid." Pharmacologically it is far closer to the muscle relaxant baclofen than to any vitamin or herb, and the clinical literature documents exactly the harms that comparison predicts: central nervous system depression severe enough to require intubation, and a withdrawal syndrome serious enough to need inpatient management.

What phenibut is

Phenibut was discovered and introduced into clinical practice in the Soviet Union in the 1960s and remains in medical use in parts of Eastern Europe for anxiety, tension, sleep problems, and a range of psychosomatic and post-traumatic conditions [1]. It has never been approved as a medicine by the U.S. Food and Drug Administration. In the United States it occupies a regulatory gap: it does not meet the statutory definition of a dietary ingredient, yet it has been widely available through online retailers that market it as a nootropic supplement [7]. That mismatch between how it is sold and what it actually is, is the root of the safety problem.

How it works

Phenibut acts primarily as an agonist at the GABA-B receptor, the same receptor targeted by baclofen, which is chemically a chlorinated derivative of phenibut. It also has weaker activity at GABA-A receptors and, at higher doses, binds the α2δ subunit of voltage-gated calcium channels [1][7]. The added phenyl ring lets it cross the blood-brain barrier, which ordinary GABA cannot do. At low doses users report calm and reduced anxiety; as the dose climbs, the effect profile increasingly resembles alcohol and benzodiazepines, with heavy sedation, slurred speech, impaired coordination, and slowed breathing.

Dependence and withdrawal

The best-documented harm from chronic phenibut use is dependence with a clinically serious withdrawal syndrome. Published case reports describe withdrawal featuring severe rebound anxiety, agitation, insomnia, hallucinations, and depressed or fluctuating consciousness [2][3]. Because the mechanism overlaps with alcohol and benzodiazepines, clinicians have managed phenibut withdrawal with the same tools used for sedative withdrawal: one reported case was treated with a baclofen taper [2], and another, in a patient already on buprenorphine, with a phenobarbital taper based on a sedative-use-disorder protocol [4]. The recurring message from these authors is that abrupt discontinuation after regular use is risky and that a medically supervised taper is safer.

What the surveillance and toxicology data show

A 2020 Morbidity and Mortality Weekly Report by Graves and colleagues analyzed phenibut exposures reported to U.S. poison centers between 2009 and 2019 and documented a marked increase over the period [5]. A single regional poison center (Minnesota) recorded 56 phenibut exposure calls over 19 years, with 48 of them (85.7%) in just the final five years; central nervous system depression was common, and 11 patients (19.6%) required intubation, though no deaths were attributed to phenibut in that series [3]. Phenibut also appears repeatedly as a co-exposure in reports on other unregulated online drugs such as tianeptine [6]. A 2020 systematic review pulled together 14 dependence and intoxication case reports (16 patients) alongside 11 clinical trials (583 patients); importantly, it found that the doses involved in the abuse and intoxication reports (0.5–100 g/day) were far above the therapeutic range described in the clinical literature (roughly 0.25–2 g/day), and that at therapeutic doses phenibut was generally well tolerated [7]. The harm signal, in other words, is concentrated in high-dose, unsupervised, often poly-substance use of online-purchased product of uncertain quality.

What acute toxicity looks like

In overdose, phenibut behaves like other central nervous system depressants. The dominant feature is reduced consciousness, which can range from heavy sedation to coma, and in the most severe cases respiratory depression requiring airway support; in the Minnesota poison-center series, about one in five exposures led to intubation [3]. Agitation, delirium, and a paradoxical hyperadrenergic state are also described, and the picture is frequently complicated by co-ingestion of alcohol, benzodiazepines, or other sedatives, which compounds the respiratory risk [3][6]. There is no specific antidote; treatment is supportive, centered on protecting the airway and supporting breathing and circulation until the drug clears. This is the core reason the comparison to a "natural anxiety aid" is misleading: the realistic worst case is not a bad night's sleep but a ventilator.

The regulatory picture

Phenibut sits in different regulatory categories in different places, but the common thread is that no major Western drug regulator has approved it as a supplement or an over-the-counter medicine. In countries where it is a prescription medicine, it is intended for supervised clinical use rather than open sale; in the United States and several other markets, regulators have taken the position that it is not a lawful dietary ingredient, even though enforcement has lagged behind online availability [7]. For a consumer, the practical reality is that a product marketed as a benign anxiety aid is an unscheduled, centrally active GABAergic drug with no quality assurance behind the label.

Sources

1. Lapin I. "Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug." CNS Drug Rev, 2001;7(4):471-81. PMID 11830761.
2. Ahuja T, Mgbako O, Katzman C, Grossman A. "Phenibut (β-Phenyl-γ-aminobutyric Acid) Dependence and Management of Withdrawal: Emerging Nootropics of Abuse." Case Rep Psychiatry, 2018;2018:9864285. PMID 29854531.
3. McCabe DJ, Bangh SA, Arens AM, Cole JB. "Phenibut exposures and clinical effects reported to a regional poison center." Am J Emerg Med, 2019;37(11):2066-2071. PMID 30878413.
4. Brunner E, Levy R. "Case Report of Physiologic Phenibut Dependence Treated With a Phenobarbital Taper in a Patient Being Treated With Buprenorphine." J Addict Med, 2017;11(3):239-240. PMID 28441273.
5. Graves JM, Dilley J, Kubsad S, Liebelt E. "Notes from the Field: Phenibut Exposures Reported to Poison Centers - United States, 2009-2019." MMWR Morb Mortal Wkly Rep, 2020;69(35):1227-1228. PMID 32881852.
6. El Zahran T, Schier J, Glidden E, et al. "Characteristics of Tianeptine Exposures Reported to the National Poison Data System - United States, 2000-2017." MMWR Morb Mortal Wkly Rep, 2018;67(30):815-818. PMID 30070980.
7. Kupats E, Vrublevska J, Zvejniece B, et al. "Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports." Pharmacopsychiatry, 2020;53(5):201-208. PMID 32340063.